Latest Insider Transactions at Aeglea Bio Therapeutics, Inc. (AGLE)
This section provides a real-time view of insider transactions for Aeglea Bio Therapeutics, Inc. (AGLE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Aeglea BioTherapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Aeglea BioTherapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 06
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Indirect |
6,700
-19.67%
|
$241,200
$36.76 P/Share
|
|
Oct 25
2024
|
Jeffrey W. Albers Director |
SELL
Open market or private sale
|
Indirect |
300
-0.87%
|
$10,800
$36.43 P/Share
|
|
Sep 03
2024
|
Scott L Burrows Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
18,531
-13.73%
|
$518,868
$28.17 P/Share
|
|
Apr 25
2024
|
Fairmount Funds Management LLC |
BUY
Exercise of conversion of derivative security
|
Indirect |
3,639,680
+47.53%
|
-
|
|
Feb 15
2024
|
Cameron Turtle Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
400
+0.05%
|
$3,600
$9.82 P/Share
|
|
Dec 29
2023
|
Fairmount Funds Management LLC |
BUY
Other acquisition or disposition
|
Indirect |
812,076
+50.0%
|
-
|
|
Dec 29
2023
|
Fairmount Funds Management LLC |
SELL
Other acquisition or disposition
|
Indirect |
3,435,480
-100.0%
|
-
|
|
Dec 22
2023
|
Scott L Burrows Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,953
+50.0%
|
-
|
|
Nov 24
2023
|
Fairmount Funds Management LLC |
BUY
Conversion of derivative security
|
Indirect |
3,435,480
+50.0%
|
-
|
|
Nov 24
2023
|
Cameron Turtle Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
723,440
+49.22%
|
-
|
|
Aug 25
2022
|
Marcio Souza Director |
BUY
Open market or private purchase
|
Direct |
90,000
+50.0%
|
$0
$0.56 P/Share
|
|
Jun 08
2022
|
Jr. Michael Conick Hanley Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
28,200
+43.79%
|
$0
$0.71 P/Share
|
|
Mar 16
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
80,079
+12.7%
|
$160,158
$2.34 P/Share
|
|
Mar 15
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
42,417
+8.22%
|
$42,417
$1.86 P/Share
|
|
Mar 14
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
67,472
+13.53%
|
$67,472
$1.93 P/Share
|
|
Mar 11
2022
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
75,000
+31.2%
|
$150,000
$2.08 P/Share
|
|
Mar 11
2022
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
34,777
+8.73%
|
$69,554
$2.06 P/Share
|
|
Dec 13
2021
|
Armen Shanafelt Director |
BUY
Open market or private purchase
|
Direct |
14,685
+8.92%
|
$44,055
$3.65 P/Share
|
|
Dec 10
2021
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
10,526
+3.1%
|
$31,578
$3.75 P/Share
|
|
Dec 10
2021
|
Armen Shanafelt Director |
BUY
Open market or private purchase
|
Direct |
13,516
+9.08%
|
$40,548
$3.65 P/Share
|
|
Dec 09
2021
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
50,000
+35.62%
|
$150,000
$3.72 P/Share
|
|
Dec 09
2021
|
Anthony G. Quinn President & CEO |
BUY
Open market or private purchase
|
Direct |
43,108
+11.93%
|
$129,324
$3.7 P/Share
|
|
Dec 09
2021
|
Armen Shanafelt Director |
BUY
Open market or private purchase
|
Direct |
121,799
+50.0%
|
$365,397
$3.67 P/Share
|
|
Aug 18
2021
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
7,200
+15.14%
|
$43,200
$6.72 P/Share
|
|
Aug 17
2021
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
23,392
+41.35%
|
$140,352
$6.5 P/Share
|
|
Aug 16
2021
|
Jonathan Alspaugh President and CFO |
BUY
Open market or private purchase
|
Direct |
9,780
+50.0%
|
$58,680
$6.37 P/Share
|
|
May 11
2018
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
19,550
-0.89%
|
$195,500
$10.06 P/Share
|
|
May 10
2018
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
22,725
-1.02%
|
$227,250
$10.13 P/Share
|
|
May 09
2018
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
51,230
-2.26%
|
$512,300
$10.11 P/Share
|
|
May 08
2018
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
26,557
-1.16%
|
$265,570
$10.03 P/Share
|
|
May 07
2018
|
Novartis Bioventures LTD |
SELL
Open market or private sale
|
Direct |
15,548
-0.67%
|
$155,480
$10.11 P/Share
|
|
Apr 12
2016
|
Novartis Bioventures LTD |
BUY
Open market or private purchase
|
Direct |
300,000
+11.49%
|
$3,000,000
$10.0 P/Share
|
|
Apr 12
2016
|
Novartis Bioventures LTD |
BUY
Conversion of derivative security
|
Direct |
2,010,924
+50.0%
|
-
|